1	Low dose oral ketamine treatment on post-traumatic stress disorder (PTSD) (OKTOP): An
2	open-label pilot study
3	
4	Bonnie L. Quigley <sup>1,2,*</sup> , Adem T. Can <sup>1,*</sup> , Megan Dutton <sup>1</sup> , Cyrana C. Gallay <sup>1</sup> , Grace Forsyth <sup>1</sup> ,
5	Monique Jones <sup>1</sup> , Fiona Randall <sup>1</sup> , Trish Wilson <sup>1</sup> , Jim Lagopoulos <sup>3</sup> , Daniel F. Hermens <sup>1,†</sup>
6	
7	*Co-first authors
8	$^1$ National PTSD Research Centre at the Thompson Institute, University of the Sunshine Coast,
9	Birtinya, QLD, 4575, Australia
10	<sup>2</sup> Centre for Bioinnovation, University of the Sunshine Coast, Sippy Downs, QLD, 4556, Australia
11	<sup>3</sup> Thompson Brain and Mind Healthcare, Maroochydore, QLD, 4558, Australia
12	<sup>†</sup> Corresponding author: Daniel F. Hermens, <u>dhermens@usc.edu.au</u>
13	
14	Keywords: ketamine, low dose oral ketamine, post-traumatic stress disorder, PTSD
15	Running title: Low dose oral ketamine trial on PTSD
16	
17	Abstract
18	Ketamine is being actively investigated as a rapid-acting treatment for many conditions with a
19	stress-related psychopathology, including post-traumatic stress disorder (PTSD). The majority of
20	studies regarding ketamine treatment for PTSD to date (including open-label and randomised
21	control trials) have focused on intravenous (IV) ketamine administration. This administration
22	route has limitations that can be overcome with oral ketamine. As such, this study undertook the
23	first open-label low dose Oral Ketamine Trial on PTSD (OKTOP) to determine the safety and
24	feasibility of sub-anaesthetic ketamine for PTSD symptom reduction. Participants with PTSD (n
25	= 22 adults, aged 22-77 years, 55% female, 82% with comorbid depression) followed a weekly
26	treatment course of low dose oral ketamine (titrated from 0.5 mg/kg to a maximum of 3.0 mg/kg)
27	for six weeks. The primary outcome measure was the PTSD Checklist (PCL-5), with secondary
28	measures including scales for depression, anxiety, stress, suicidality, sleep, and wellbeing.
29	Mean PCL-5 scores were significantly reduced from a pre-ketamine baseline score of 40 to a
30	post-ketamine score of 17 and remained at a reduced score (21) at follow-up, 1-month post-
31	treatment. This reduction resulted in a response rate (defined as a $\geq$ 50% reduction in PCL-5 score
32	from baseline) of 73% post-ketamine and 59% at follow-up. This response rate is comparable
33	with IV ketamine trials for PTSD and suggests oral ketamine administration is a feasible and
34	tolerable treatment for PTSD.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

#### 35 Introduction

36 Up to 70% of people experience at least one traumatic event in their lifetime (Benjet et 37 al., 2016). Whilst most people will suffer only short-term impacts from such events, ~10% will go on to experience the prolonged symptoms characteristic of post-traumatic stress disorder 38 39 (PTSD) (Australian Bureau of Statistics 2020-21). The Diagnostic and Statistical Manual of Mental 40 Disorders (5<sup>th</sup> ed) (DSM-5) categorises PTSD within the Trauma- and Stressor-Related Disorders 41 (American Psychiatric Association, 2013). In addition to having trauma exposure, there are four symptom clusters integral and necessary to a diagnosis of PTSD: (1) re-experiencing (intrusive 42 43 thoughts, flashbacks, nightmares), (2) avoidance (of contextual or geographical triggers/reminders or internal sensations (thoughts, memories, physical symptoms)), (3) 44 increased negative affect (depression, hopelessness, difficulty concentrating), and (4) 45 46 hyperarousal (heightened physiological and emotional reactivity) (American Psychiatric 47 Association, 2013). To complete the diagnostic criteria, symptoms must be present for at least 48 one month, not be caused by drugs or other illnesses, and cause significant functional 49 impairment (American Psychiatric Association, 2013).

PTSD can develop from trauma exposure in various settings and have profound impacts 50 51 on those affected. The highest rates of PTSD have been reported in survivors of sexual assault, 52 military war and imprisonment, and genocidal crimes worldwide (American Psychiatric Association, 2013). Epidemiological data reveals that over 90% of individuals with PTSD 53 experience a comorbid psychiatric disorder including suicidal ideation, anxiety, alcohol use 54 55 disorders, and depression (Sareen, 2014). In fact, individuals with PTSD are 80% more likely than 56 individuals without PTSD to meet the diagnostic criteria for at least one additional mental illness (American Psychiatric Association, 2013). Specifically, one study found 77% of women and 86% 57 58 of men with PTSD also had another disorder, such as affective (51% women, 52% men), anxiety 59 (52% men, 54% women), or substance use disorders (Mills et al., 2011). Overall, PTSD is often linked to poor social and familial relationships, job absenteeism, and lower income, 60 61 educational attainment, and occupational accomplishment (American Psychiatric Association, 62 2013).

63 In contemporary clinical settings, PTSD treatment often includes a combination of psychological and pharmacological interventions (Green, 2013; Thomas and Stein, 2017). 64 Trauma-focused psychotherapies with the largest current evidence base are exposure-based 65 treatments and include Prolonged Exposure (PE), Cognitive Processing Therapy (CPT), trauma-66 focused Cognitive Behavioural Therapy (CBT), and Eye Movement Desensitization and 67 68 Reprocessing (EMDR) (Norman et al., 2023; Watkins et al., 2018). Exposure therapy decreases

2

69 symptoms by having patients envision themselves exposed to stimuli rather than avoiding them. 70 By encouraging adaptive associations with painful memories, this approach improves inhibitory 71 learning and reduces suffering, rendering the trauma tolerable (López-Ojeda and Hurley, 2022). 72 These therapeutic interventions concentrate on the cognitions, emotions, memories, and 73 thoughts that are linked to the traumatic events (López-Ojeda and Hurley, 2022; Watkins et al., 74 2018). Beyond exposure-based treatments, alternatives like Reconsolidation Therapy (RT), which focuses on how traumatic events are stored as memories (Brunet et al., 2021), are being 75 76 investigated. However, further research is needed in this space to establish robust alternatives 77 to current exposure-based psychotherapies.

78 Pharmacotherapy for PTSD is an option when psychotherapy has been found ineffective, 79 individual patients have different preferences, or individuals cannot directly engage in 80 psychotherapy (especially in the initial presentation). Standard PTSD treatment protocols 81 suggest antidepressants, particularly selective serotonin reuptake inhibitors (SSRIs), as the first-82 line treatment medication for PTSD (Asnis et al., 2004). However, SSRIs are known to take up to six weeks to reduce hyperarousal, anxiety, suicidal thoughts, and depressive symptoms (Frazer 83 84 and Benmansour, 2002). Two SSRIs are FDA-approved for PTSD treatment, paroxetine and 85 sertraline, and collectively, response rates to these drugs rarely exceed 60%, with less than 30% 86 of patients achieving full remission (Asnis et al., 2004; Berger et al., 2009). Sleep disruption, 87 drowsiness, sexual dysfunction, weight gain, withdrawal symptoms, and decreased therapeutic response are all commonly reported with chronic SSRI use and limit their overall efficacy 88 89 (Ferguson, 2001). Similar to SSRIs, selective serotonin and norepinephrine reuptake inhibitors 90 (SNRIs) have been evaluated in PTSD, but also show limited efficacy and often leave 91 residual symptoms (Jeffreys et al., 2012). Other drug classes, including monoamine oxidase 92 inhibitors (MAOIs) and tricyclic antidepressants (TCAs), are sometimes considered, but have 93 limited utility due to higher adverse effects and safety issues (Asnis et al., 2004). Finally, some small improvements have been reported with atypical antipsychotics, which can be used with 94 95 antidepressants. Atypical antipsychotics can have mood stabilising properties, improve sleep 96 patterns (decreasing the frequency of nightmares) and reduce the frequency of flashbacks and 97 intrusive thoughts (Adetunji et al., 2005). However, they are considered primarily an adjunct to standard treatments in selectively warranted cases. 98

Ketamine, an N-methyl-D-aspartate-type glutamate (NMDA) receptor antagonist, has
been used in medicine as an aesthetic and analgesic since the 1970s (Kurdi et al., 2014). Starting
around 2000, low dose (i.e. sub-anaesthetic) ketamine began being tried off label for treatmentresistant depression (TRD), with studies in this space continuing to today (Berman et al., 2000;

103 Ragnhildstveit et al., 2023). Although intravenous (IV) infusion is the most common route of administration, a ketamine nasal spray formulation received FDA approval in 2019 for the 104 105 treatment of TRD (Kim et al., 2019). Investigations into ketamine's effectiveness for PTSD 106 treatment began appearing in the literature in 2005 and, to date, systematic review has identified 107 26 studies that retrospectively or prospectively examined ketamine use for PTSD in the form of 108 case studies (n=7), chart reviews (n=7), open-label studies (n=5) or randomised control trials 109 (RCTs) (n=7) (Ragnhildstveit et al., 2023). Of these PTSD ketamine studies, the vast majority have 110 employed IV infusion as the route of ketamine administration (in four of the case studies, five of 111 the chart reviews and all the open-label studies and RCTs) (Ragnhildstveit et al., 2023). 112 Representing the other routes of ketamine administration, intranasal and intramuscular 113 administration has been reported from one case study and one chart review each, while oral 114 ketamine administration has been reported on from one case study and two chart reviews (Ragnhildstveit et al., 2023). Since that systematic review, an additional oral ketamine 115 116 administration case study report has been published (Veraart et al., 2023).

117 Because open-label studies and RCTs have been limited to IV ketamine administration in the PTSD treatment space, there is a significant gap in our knowledge regarding the safety, 118 119 tolerability, and efficacy of ketamine for PTSD delivered by non-IV routes. While IV ketamine has 120 been found to be safe and well tolerated in open-label studies and RCTs (Ragnhildstveit et al., 121 2023), this method must be administered in a hospital or clinic setting under medical supervision, making it difficult to implement in conventional clinical psychiatry. This limits its use 122 123 in ambulatory settings, especially for treatment programs that require daily or intermittent dosing 124 schedules (Andrade, 2019). Alternatively, the oral administration of ketamine is more practical 125 and the simplest route for implementation, giving it higher clinical applicability. Oral ketamine 126 also has a much lower cost compared to other administration forms, offering a significant 127 opportunity for financially disadvantaged cohorts (Andrade, 2019; Can et al., 2021; Muhorakeye 128 and Biracyaza, 2021).

129 Collectively, the advantages of oral ketamine as a viable treatment for individuals with 130 PTSD warrants further investigation to determine its potential efficacy. However, a substantial 131 amount of knowledge remains deficient concerning dosage levels, treatment protocols, and the feasibility and safety of ketamine use over the short- and long-term when administered orally. To 132 investigate this matter, the current research conducted an open-label, flexible-dose, 6-week trial 133 134 of oral ketamine, followed by a 4-week follow-up phase without ketamine. The purpose of the 135 trial was to evaluate the efficacy and safety of the medication, as well as the acute and prolonged 136 responses, in the treatment of PTSD. The primary outcome measure was change in PTSD-related

scales (PCL-5). We hypothesized that the administration of oral ketamine, once weekly for six
weeks, would result in a reduction in PTSD symptomatology from a pre-ketamine baseline to a
post-treatment follow-up.

140

# 141 Methods

## 142 Ethics approval and consent

Metro North Health Human Research Ethics Committee (HREC) granted approval for this study (Project ID: 42836; HREC/18/QPCH/28), and the University of the Sunshine Coast HREC subsequently confirmed that approval (A181190). The study was conducted in adherence to the ethical guidelines outlined in the Declaration of Helsinki. Every participant delivered a written consent that was well-informed. Fuel vouchers served as the form of compensation. The trial was officially documented with the Clinical Trials Registry of Australia and New Zealand (ACTRN12618001965291).

150

#### 151 Participants

Psychiatrists and local general practitioners (GPs) were notified of the trial through clinic visits and telephone conversations. Approved advertising materials were provided to local GP clinics and hospitals and were made available on our website. The study recruited participants who had received a diagnosis of PTSD from their general practitioners, psychiatrists, and psychologists in the area.

The study recruited individuals who were 18 years of age or older and had a confirmed diagnosis of PTSD, as determined by the Clinician Administered PTSD Scale for DSM-5 (CAPS-5) (Weathers et al., 2018). The principal investigator (a consultant psychiatrist) confirmed this through comprehensive psychiatric evaluation and mental state evaluation of the participants and the administering of a CAPS-5 assessment. Participants who were assessed for the study but were not enrolled were documented by the investigators. Eligible participants for the study were those who fulfilled all the inclusion criteria and did not satisfy any of the exclusion criteria.

Exclusion criteria were (1) Psychiatric conditions: (a) psychosis, (b) mania or hypomania, (c) acute suicidality requiring urgent psychiatric intervention and (d) a history of ketamine use disorder, (2) Physical conditions: (a) participants who have history of epilepsy or unexplained seizure history, (b) uncontrolled/severe symptomatic cardiovascular disease states including recent myocardial infarction (within prior 6 months), history of stroke and hypertension (resting blood pressure >150/100), (c) body weight of >150 kg, (d) history of intracranial mass, intracranial haemorrhage/stroke, cerebral trauma/traumatic brain injury or increased intracranial pressure

(as assessed by referring general practitioner), (f) liver function test (LFT) results out of normal range, (g) previous reaction to ketamine (as reported by referring general practitioner and participant), (h) participants who are pregnant, currently breastfeeding, or who are planning a pregnancy during the trial, (i) participants who are simultaneously engaging in another clinical intervention, (j) participants with a history of substance use disorder (excluding ketamine use disorder) may be eligible to participate in the study if they abstain from alcohol or illicit substance use two weeks prior to participation in the trial and for the remainder of the trial.

178 The physical health of all participants was evaluated through a comprehensive assessment 179 that included physical examination, laboratory blood testing, and a review of their medical history 180 conducted by the primary investigator/psychiatrist. Throughout the treatment and follow-up phase, participants continued their regular prescribed medication as directed by their respective 181 182 healthcare providers. Most individuals in the study were concurrently taking psychopharmacological drugs, such as SSRIs, SNRIs, antipsychotics and mood stabilisers (Table 183 184 1).

185

Table 1. CAPS-5 scores, co-morbidities, concomitant psychotropic medications, and index
 trauma of study participants at the baseline assessment.

ID CAPS-5 Additional DSM-5		Additional DSM-5 diagnoses	Psychotropic medications	Index
	score			trauma
01 🗖	43	none	Clonidine, Fluoxetine, Lyrica, Seroquel	Childhood
03 🔵	46	cPTSD, MDD, GAD	Diazepam	SA/DV
04 📥	46	GAD, Chronic insomnia, MDD	none	Childhood
05 🔷	50	MDD	Desvenlafaxine, Quetiapine	Military
13 🗖	57	OSFED, MDD	Escitalopram	MVA
15 🛑	52	MDD, PDD	Duloxetine, Diazepam, Mirtazapine	Death of Child
18 🛆	48	MDD, GAD	Melatonin	Military
21 🔷	64	MDD, SUD	Fluoxetine, Diazepam	Childhood
27	56	MDD, GAD	Duloxetine, Diazepam	Childhood
28 🔘	54	MDD	Spectrum red THC oil, Medcan fx04	Military
29 🛆	42	MDD, Chronic insomnia	Zopiclone, Temazepam, Diazepam, CBD oil	Military
30 🔶	57	MDD	Agomelatine	Childhood
31 🗖	61	MDD	Paroxetine	Workplace
35 🔵	51	GAD	Escitalopram	Childhood
37 🛆	58	MDD, PMDD	none	SA/DV
40 🔶	54	MDD	none	Workplace
46	53	MDD	Duloxetine, Mirtazapine, Periciazine	Workplace
49 🔾	54	MDD	Duloxetine, Diazepam	Childhood

50 🛆	53	cPTSD, Chronic insomnia	Diazepam, Pregabalin	Childhood
51 🔶	57	MDD	Melatonin, Phenergan	Childhood
52 🗖	51	none	none	Military
53 🔘	67	ADHD, MDD	Dexamphetamine, Oxazepam, Temazepam	Childhood

All participants met the diagnostic criteria for PTSD as assessed by Clinician Administered 188 PTSD Scale for DSM-5 (CAPS-5). Additional DSM-5 diagnoses: ADHD - Attention-Deficit / 189 190 Hyperactivity Disorder, cPTSD - complex PTSD, GAD - Generalised Anxiety Disorder, MDD -191 Major Depressive Disorder, OSFED - Other Specified Feeding or Eating Disorder, PDD -192 Persistent Depressive Disorder (Dysthymia), PMDD - Premenstrual Dysphoric Disorder, SUD -Substance Use Disorder (in remission). Psychotropic medications: CBD - Cannabidiol, THC -193 194 Delta-9-tetrahydrocannabinol. Index traumas: SA/DV – sexual assault/domestic violence, MVA 195 - motor vehicle accident.

196

197 Following the provision of informed consent, a psychiatric review was conducted by the 198 psychiatrist and study nurses in the form of a semi-structured interviews to elicit a diagnosis of 199 PTSD and any comorbidities (Table 1), and subsequent eligibility for the study, including all 200 wellbeing and safety scales. Data pertaining to demographic details, concomitant pharmaceutical treatment and medical conditions were also collected. Vital signs, blood tests 201 202 and urinalysis were taken to establish baselines and confirm the absence of contraindications (e.g., uncontrolled hypertension and pregnancy). A registered nurse undertook vital signs and 203 204 urinalysis.

205

#### 206 Study design and treatment

207 From August 2021 to January 2024, this open-label trial of oral ketamine was conducted at the Thompson Institute, University of the Sunshine Coast. A 6-week flexible-dose course of 208 209 oral (racemic) ketamine was administered for the treatment for PTSD, followed by a 4-week 210 follow-up phase (i.e., without ketamine) to evaluate the dosing regimen, safety/tolerance, and 211 acute and prolonged response rates to once-weekly oral ketamine administration.

212 In the fourteen days prior to the commencement of ketamine treatment, all participants 213 underwent a baseline assessment that included a physical examination, urinalysis, laboratory 214 blood testing, and review of their medical history. Over a 6-week treatment period, each participant was administered one dose of ketamine per week as an oral subanesthetic. Ketamine 215 was prescribed by the consultant psychiatrist and administered as a liquid in fruit juice at an 216 217 initial dosage of 0.5 mg/kg by the registered nurse or nurse practitioner. Depending on patient 218 tolerance, dose amounts were increased by 0.1–0.5 mg/kg at each treatment, to a maximal dose of 3.0 mg/kg at the sixth treatment. The assessment of urinalysis and the presence or absence of 219 220 adverse effects, as determined by tolerability and safety rating instruments, was employed to

221 ascertain ketamine intolerance. Participants were under immediate post-treatment supervision 222 for a minimum of sixty minutes. For twelve hours post-treatment, participants were instructed to refrain from engaging in activities that demanded alertness (such as operating a motor vehicle), 223 adhering to work, or entering legal contracts. On the day of the treatment, they were also required 224 225 to arrange for appropriate transportation to and from the location (not allowed to drive 226 themselves). The overall trial design is illustrated in Figure 1, which highlights three significant time points: (i) "pre-ketamine" (up to -2 weeks prior to first treatment), which comprised the 227 228 "baseline" timepoint; (ii) "post-ketamine", which occurred 1–7 days after the final treatment, and 229 (iii) "follow-up," which occurred 28-32 days after the final treatment, respectively. Phone 230 evaluations were conducted 24-hours post-treatment to monitor for adverse effects.



232 Figure 1. Oral Ketamine Trial on PTSD (OKTOP) study design. Following written consent and eligibility confirmation, OKTOP participants underwent a pre-ketamine baseline assessment 233 234 which included physical examination, urinalysis, laboratory blood testing, review of medical 235 history, full clinical scales assessment (including CAPS-5 for baseline only), research blood 236 collection, magnetic resonance imaging (MRI) and electroencephalogram (EEG) imaging, and 237 cognitive functioning assessment. During ketamine treatment, weekly assessments included 238 physical examination, urinalysis, and full clinical scales assessment, with treatment weeks 3 239 and 6 also collecting research bloods and MRI & EEG imaging. Post-ketamine and Follow-up 240 assessments included full clinical scales assessment, laboratory blood testing, research blood 241 collection, MRI & EEG imaging, and cognitive functioning assessment. This report focuses on the 242 clinical scale assessment outcomes only.

243

#### 244 Assessments

245 Physical assessments were conducted at each study visit to monitor participant health 246 and determine adverse events. At pre-ketamine baseline and prior to all treatments, urinalysis, using a bedside test, was performed by clinical staff to screen for cystitis. Urine pregnancy 247 screening was undertaken for females of childbearing age at the pre- and post-ketamine time 248 249 points, as well as pregnancy tests as required. At each treatment visit, vital signs (heart rate, 250 blood pressure, oxygen saturation level, and temperature) were recorded three times: before 251 ketamine delivery and at 30- and 60-minutes post-treatment. Standard clinical pathology laboratory blood testing was performed at pre-ketamine baseline, post-ketamine and follow-up 252

and included Full Blood Count (FBC), Urea and Electrolytes (UE), LFT, and Thyroid Function Test(TFT).

255 In addition to the CAPS-5 assessment (Weathers et al., 2018) conducted at pre-ketamine 256 baseline, the following clinical rating scales were completed by participants at baseline, post-257 ketamine and follow-up timepoints to evaluate the primary and secondary trial outcomes: (a) 258 PTSD Checklist for DSM-5 (PCL-5), a 20-item self-report measure often used in conjunction with 259 the CAPS-5 to monitor PTSD symptom change across patient treatment (Blevins et al., 2015; 260 Weathers et al., 2018); (b) Life Events Checklist for DSM-5 (LEC-5), a 17-item self-report measure 261 designed to evaluate participant's exposure to potentially traumatic events across the lifetime, 262 often used in conjunction with CAPS-5 (baseline only) (Elhai et al., 2005); (c) Beck Scale for 263 Suicide Ideation (BSS), a 21-item clinician-rated scale which examines suicidal intent in patients 264 (Beck et al., 1979); (d) Montgomery-Asberg Depression Rating Scale (MADRS), a 10-item 265 clinician-rated scale used to measure the severity of depressive symptoms (Montgomery and 266 Asberg, 1979); (e) Depression, Anxiety, and Stress Scale (DASS-21), 21-item self-report measure 267 assessing perceived depressive, anxiety, and stress symptoms (Lovibond and Lovibond, 1995); 268 (f) Social and Occupational Functioning Assessment Scale (SOFAS), a clinician-rated single-item 269 scale used to indicate an individual's level of social and occupational functioning (Goldman et 270 al., 1992); (g) World Health Organization Well-Being Index (WHO-5), a 5-item self-report global 271 rating scale measuring subjective well-being (Bech et al., 2003); (h) Pittsburgh Sleep Quality Index -Addendum for PTSD (PSQI-A), a 7-item self-report measure assessing frequency of 272 disruptive nocturnal behaviours specific to PTSD (Germain et al., 2005); (i) Perceived Stress Scale 273 274 (PSS), 10-item self-report measure assessing a patient's perception of stress (Cohen et al., 275 1983); (j) Snaith-Hamilton Pleasure Scale (SHAPS), 14-item clinician-rated scale evaluating 276 anhedonia for neuropsychiatric disorders (Franken et al., 2007).

277 The following safety and tolerability measures were also collected 60 min after each 278 ketamine dose in-person and 24-hours post-treatment via a phone call: (a) Patient Rated 279 Inventory of Side Effects (PRISE), 33-item self-report measure assessing side-effects within 280 specific symptom domains across the past 7 days (Rush et al., 2004); (b) Clinician Administered 281 Dissociative States Scale (CADSS), a structured clinical interview used to check for present-state dissociative symptoms (Bremner et al., 1998); (c) Brief Psychiatric Rating Scale (BPRS), an 18-282 item clinician-rated scale used as a general measure of psychiatric symptoms such as 283 284 depression, anxiety, hallucinations and unusual behaviour (Overall and Gorham, 1988); (d) 285 Young Mania Rating Scale (YMRS), a 11-item clinician-rated scale used to check for elevated

286 mood (i.e. mania) (Young et al., 1978). CADSS, BPRS and YMRS items relating to positive287 symptoms were closely monitored for potential side effects.

288

#### 289 Outcome measures

290 The primary outcome measure for the study was a reduction in PTSD symptomology with 291 ketamine treatment, as determined by the PCL-5 scale. A 'response' was defined as a  $\geq$ 50% 292 improvement in PCL-5 score from the pre-ketamine to the post-ketamine visit. A 'prolonged 293 response' was defined as a  $\geq$  50% improvement in PCL-5 score from pre-ketamine to the follow-294 up visit. Secondary outcome measures included pre-ketamine to follow-up changes in BSS, 295 DASS-21 (as the three individual subscales of anxiety, depression, and stress), MADRS, SOFAS, 296 and WHO-5 scores. Additionally, PSQI-A, PSS and SHAPS-C scores were also evaluated pre-297 ketamine to follow-up.

298

### 299 Analysis

Statistical analyses were carried out using SPSS Statistics for Windows, version 27 (IBM Corp, 300 301 Armonk, NY). Assumptions were checked for all analyses and reported in results. To test the 302 primary outcome, a repeated measures ANOVA was conducted with time as the within subjects' factor (three levels: pre-ketamine, post-ketamine and follow-up timepoints) and PCL-5 as the 303 304 dependent variable. Pairwise comparisons of the timepoints were performed with Bonferroni 305 corrections. Cohen's d effect sizes were also calculated to further describe differences between 306 timepoints. Repeat measure ANOVAs were additionally conducted for secondary outcomes, 307 BSS, MADRS, DASS, SOFAS and WHO-5, as well as PSQI-A, PSS and SHAPS-C, as described 308 above, with three levels of time. For all tests, significance thresholds were set at p < 0.05.

309

### 310 Results

Of the 131 participants pre-screened for this study, n=59 met initial eligibility and n=38 311 312 were enrolled in the study. Of these, six participants failed to attend the baseline assessment 313 and subsequently withdrew, and five participants failed to meet final eligibility (did not meet CAPS-5 requirement or medical criteria during the baseline assessment). Of the remaining 27 314 315 participants, five participants missed more than one treatment week and/or the post-treatment or follow-up assessment and were removed from analysis. This resulted in a final study cohort of 316 317 n=22 participants that met all eligibility criteria and completed all required treatments and 318 assessments.

319 The study cohort (12 female, 10 male) had a mean age of  $47.07 \pm 13.76$  years (range 320 22.39-77.93 years) and a mean weight at first treatment of 90.85 ± 23.52 kg. In addition to PTSD, 321 n=18 (82%) met DSM-5 criteria for comorbid major depressive disorder (MDD) and n=5 (26%) met 322 criteria for comorbid generalised anxiety disorder (GAD). Additionally, n=5 (23%) were 323 medication-free at trial commencement. The Index Event trauma reported varied for participants 324 and included childhood trauma (n=10, 45%), military trauma (n=5, 23%), workplace trauma (n=3, 14%), sexual assault/domestic violence (n=2, 9%), motor vehicle accident (n=1, 5%) and death 325 326 of a child (n=1, 5%) (Table 1).

327

# 328 **Primary outcome measure**

329 The mean PCL-5 score was significantly reduced at both post-ketamine ( $16.96 \pm 16.18$ , 330 n=22; range=0–57) and follow-up (21.05 ± 16.62, n=22; range=0–63) timepoints (Figure 2) when compared to the pre-ketamine timepoint  $(40.32 \pm 11.61, n=22; range=12-61)$ . This was 331 332 confirmed by omnibus ANOVA (main effect of time; p < 0.001) and significant pairwise comparisons between pre-ketamine and post-ketamine (p < 0.001; d=1.30) and follow-up (p333 334 <0.001; d=1.05) timepoints, respectively. There was a small increase in the PCL-5 score from 335 post-ketamine to follow-up, however this was not significant (pairwise comparison, p=0.110; 336 d=-0.47). Thus, at the group level, the PCL-5 score reduced to below the clinical threshold 337 score of 31 at the post-ketamine timepoint. Furthermore, the mean follow-up PCL-5 score remained at almost half of the mean pre-ketamine PCL-5 score. 338 The proportion of PCL-5 responders (participants with  $\geq$ 50% reduction in PCL-5 score) 339 340 was 73% at post-treatment and remained at 59% at follow-up (prolonged responders). Notably, 341 n=12 participants were responders at both post-ketamine and follow-up timepoints.

342



#### Figure 2. PTSD Checklist for DSM-5 (PCL-5) scores at major study timepoints. Points 344 represent individual participant PCL-5 scores at Pre-ketamine (baseline), Post-ketamine (1-week 345 post-treatment), and Follow-up (1-month post-treatment). Dashed red line signifies threshold 346 (>31) indicative of a PTSD diagnosis by PCL-5. Mean and 95% confident interval (CI) are indicated 347 348 by the red circle and error bars, respectively. (Note - all participants met criteria for a clinical 349 diagnosis of PTSD by CAPS-5 at Pre-ketamine.)

350

343

#### Secondary outcome measures 351

The secondary outcome measures, also collected at pre-ketamine, post-ketamine, and follow-352 353 up timepoints, all showed significant reductions (Table 2). Specifically, the BSS scores reduced 354 from 5.68 pre-ketamine to 1.73 post-ketamine and 2.36 at follow-up (p<0.001) and, while the mean score for this scale was below the clinical threshold at baseline, this reduction represented 355 356 a significant lowering of suicidality risk in this cohort. Additionally, the MADRS score decreased 357 from 32.77 at pre-ketamine (severe depression range) to 8.55 post-ketamine and 9.91 at follow-358 up (mild depression range). The self-rated DASS scale showed significant reductions from preketamine to post-ketamine and follow-up across all 3 subscales (p<0.001). Notably, DASS 359 360 scores at the post-ketamine timepoint were all in the 'Normal' range, with anxiety and stress 361 subscales remaining 'Normal' at follow-up, and the depression subscale elevating to only the

362 'Mild' range. SOFAS scores, indicative of social and vocational functioning, significantly 363 improved from 59.55 pre-ketamine to 76.82 post-ketamine. The self-rated WHO-5 showed a 364 highly significant improvement in quality of life, from 28.55% at pre-ketamine to 54.55% post-365 ketamine (above 50% threshold for depression) and dipping slightly to 49.64% at follow-up. 366 Finally, additional measures for sleep (PSQI-A), perceived stress (PSS) and pleasure (SHAPS) all 367 showed significant improvements at post-ketamine and follow-up (Table 2).

368

370

### 369 Table 2. Mean scores (± standard deviation) for secondary outcomes at pre-ketamine, post-

ketamine and follow up time-points for N=22.

Scale	Pre-ketamine	Post-ketamine	Follow-up	Sig. test (p), Partial Eta
BSS	5.68 ± 4.98	1.73 ± 3.31	2.36 ± 3.27	F (2,42) =10.12, p<0.001, partial η <sup>2</sup> =.33
MADRS	32.77 ± 6.70	8.55 ± 9.99	9.91 ± 8.99	F (2,42) =107.0, p<0.001, partial $\eta^2$ = .84
DASS-D	19.00 ± 9.15	8.00 ± 8.77	11.27 ± 10.28	F (2,42) =13.14, p<0.001, partial η²=.39
DASS-A	13.91 ± 8.45	4.82 ± 8.46	6.55 ± 8.10	F (2,42) =13.61, p<0.001, partial $\eta^2$ =.39
DASS-S	21.36 ± 10.39	10.36 ± 9.57	12.91 ± 10.98	F (2,42) =11.71, p<0.001, partial $\eta^2$ =.36
SOFAS	59.55 ± 18.64	76.82 ±15.85	75.91 ± 17.90	F (2,42) =13.28, p<0.001, partial $\eta^2$ =.39
WHO-5	28.55 ± 17.64	54.55 ± 23.67	49.64 ± 29.77	F (2,42) =15.28, p<0.001, partial $\eta^2$ =.42
PSQI-A	7.32 ± 4.13	3.32 ± 3.54	4.18 ± 4.62	F (2.42) =10.41, p<0.001, partial $\eta^2$ =.33
PSS	23.27 ± 6.61	14.09 ± 8.05	15.64 ± 7.51	F (2,42) =17.56, p<0.001, partial $\eta^2$ =.46
SHAPS	32.14 ± 6.97	25.68 ± 8.05	27.00 ± 9.22	F (2,42) =6.31, p=0.004, partial η² =.23

Scales: BSS - Beck Scale for Suicide Ideation, MADRS -Montgomery-Åsberg Depression Rating
Scale, DASS-D - Depression Anxiety and Stress Scale-Depression subscale, DASS-A Depression Anxiety and Stress Scale-Anxiety subscale, DASS-S - Depression Anxiety and Stress
Scale-Stress subscale, SOFAS - Social and Occupational Functioning Assessment Scale, WHO5 - World Health Organisation-Five Well-Being Index, PSQI-A - Pittsburgh Sleep Quality Index –
Addendum for PTSD, PSS – Perceived Stress Scale, SHAPS - Snaith-Hamilton Pleasure Scale

#### 378 Adverse events and side effects

No serious adverse events were recorded during the study. Transient changes in vital signs were observed throughout treatment but no significant variations in heart rate, respiratory rate or oxygen saturation were observed. The treatment was generally well tolerated, with no participants withdrawing from the trial due to adverse side effects due to the ketamine.

The most frequent side effects reported throughout the six weeks of ketamine treatment were difficulty sleeping, headache, anxiety, fatigue, poor concentration, decreased energy, followed by restlessness, general malaise, dry mouth, dizziness, and dry skin (**Table 3**). These side effects were consistent with those observed in a similar low dose oral ketamine trial for

- 387 suicidality (Can et al., 2021). Reports of distressing side effects decreased from 4% of total
- symptoms monitored at treatment 1 to between 1-2% for treatments 2-6 (Table 3). 388
- 389

#### 390 Table 3. Adverse symptoms from Patient Rated Inventory of Side Effects (PRISE).

Symptoms	Tx1	Tx2	Tx3	Tx4	Tx5	Tx6
Gastrointestinal symptoms						
Diarrhea	3/1	1/0	4/0	4/0	1/0	4/0
Constipation	1/0	1/1	1/1	0/0	1/0	3/0
Dry mouth	7/1	9/0	5/0	7/1	8/0	8/0
Nausea/vomiting	2/0	4/0	0/0	4/0	5/0	3/0
Heart symptoms						
Palpitation (skipping a beat)	0/0	0/0	0/0	2/0	1/0	3/0
Dizziness on standing	3/0	2/0	2/0	3/0	3/0	3/0
Chest pain	0/0	0/0	0/0	1/0	0/0	2/0
Skin symptoms						
Rash	0/0	0/0	1/0	0/0	0/0	0/0
Increased perspiration	3/1	1/1	1/0	2/0	3/0	0/1
Itching	1/0	2/0	1/0	3/0	2/0	4/0
Dry skin	5/1	3/1	2/1	2/1	3/1	5/1
Nervous system symptoms						
Headache	11/1	4/0	7/1	7/2	6/1	8/0
Tremors	0/0	2/0	0/0	2/0	2/0	2/0
Poor coordination	2/0	1/0	1/0	0/0	2/0	1/0
Dizziness	4/0	4/0	2/0	5/0	4/0	3/0
Eyes / ears symptoms						
Blurred vision	1/1	1/1	1/0	1/0	1/1	2/1
Ringing in ears	3/0	5/0	4/0	3/1	3/1	5/0
Urinary / menstrual symptoms						
Difficulty urinating	0/0	0/0	0/0	0/0	0/0	0/0
Painful urination	0/0	0/0	0/0	0/0	0/0	0/0
Frequent urination	2/0	1/0	3/0	3/0	3/0	3/0
Menstrual irregularity	1/1	1/0	2/0	2/0	2/0	0/0
Sleep symptoms						
Difficulty sleeping	5/5	7/2	7/2	9/2	5/2	10/1
Sleeping too much	0/1	0/1	1/1	2/0	0/1	1/1
Sexual functioning symptoms						
Loss of sexual desire	2/0	2/0	2/0	1/0	1/0	0/0
Trouble achieving orgasm	1/0	2/0	1/0	1/0	1/0	0/0
Trouble with erections	0/0	0/0	0/0	0/0	0/0	0/0
Other symptoms						
Anxiety	8/4	9/0	12/0	11/0	8/0	9/0
Fatigue	6/4	8/2	8/2	7/2	5/3	7/1
Poor concentration	7/3	7/1	8/1	8/0	8/2	7/0
Decreased energy	6/2	9/1	8/1	8/0	5/1	5/1
General malaise (discomfort)	1/0	3/1	4/0	6/0	3/0	2/0
Restlessness	6/1	7/0	7/0	9/0	5/0	6/0

medRxiv preprint doi: https://doi.org/10.1101/2024.11.26.24318024; this version posted December 5, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Other4/21/01/01/11/0391Reported as N(tolerable)/N(distressing) from n = 22 participants at 24 hr post-ketamine392treatment weekly.

393

394 Dissociation symptoms were monitored via the CADSS clinical interview 60 min post-395 treatment throughout the treatment schedule, as ketamine dosage increased each week based 396 on patient tolerance. At treatment 1 (with a dosage of 0.5 mg/kg), six participants (27%) reported 397 mild effects ("I feel slightly detached from what is going on, but I am basically here"), while only 398 one participant reported moderate effects ("Things seem dreamlike, although I know I am 399 awake"). As treatments continued, dissociation effects remained limited, with most effects 400 reported as mild or moderate. Severe dissociation was only reported from one participant at 401 treatment 4 and two participants at treatment 5 and 6, while extreme dissociation was only 402 reported from one participant at treatment 5. These effects dissipated quickly and did not impact 403 the treatment schedule.

BPRS positive symptoms (delusion, conceptual disorganisation, hallucination, excitement, grandiosity, suspiciousness, hostility) were monitored 60 min post-treatment. Only two participants returned a rating above mild at any point in the study (one at treatment 1 (elevated suspiciousness and hostility) and one at treatment 3 (elevated hostility), however, reevaluation at 24-hour post-treatment determined that these symptoms had subsided.

Finally, YMRS scores were all below the threshold for mania, with only one participant
having a score of 5 the day after treatment 5 (due to less sleep and irritability) and the remainder
of participants scoring 4 or below throughout the treatment period.

412

#### 413 Discussion

414 To the best of our knowledge, this study is the first to explore the feasibility, safety, and 415 tolerability of low dose oral ketamine in an open-label clinical trial for PTSD treatment. In this 416 pilot study, six weeks of oral ketamine (administered once a week in liquid form as a drink), led 417 to significant decreases in PCL-5 scores (the primary outcome measure) from pre-ketamine 418 baseline to post-ketamine and follow-up assessments. This represented 73% of participants 419 being classified as responders to the oral ketamine treatment (>50% reduction in PCL-5 score at 420 the 1-week post-treatment assessment) and 59% of participants going on to be prolonged responders (maintained that ≥50% reduction in PCL-5 score at the 1-month follow-up 421 assessment). These results are comparable to current IV ketamine trial outcomes for PTSD 422 423 treatment (Ragnhildstveit et al., 2023).

424 In addition to significant improvements in PTSD symptomology (captured by the PCL-5), 425 several other self-reported and clinician-rated scales also showed significant improvements 426 with low dose oral ketamine treatment. This is an important finding, as over three-quarters of 427 individuals diagnosed with PTSD are found to meet the criteria for at least one additional mental 428 illness (American Psychiatric Association, 2013). In this study, low dose oral ketamine was seen 429 to significantly improve co-morbid symptoms related to depression (via MADRS and DASS-D), 430 suicidal ideation (via BSS), anxiety (via DASS-A), and stress (via DASS-S and PSS), as well as 431 improve social and occupational functioning (via SOFAS), sleep (via PSQI-A) and overall pleasure 432 and wellbeing (via SHAPS and WHO-5). These co-morbidities or functional impairments add a 433 substantial burden to individuals living with PTSD. The finding that ketamine can improve this 434 spectrum of symptoms in a short period of time is promising for future trials to determine efficacy 435 and treatment strategies.

436 A deliberate and important aspect to this open-label pilot trial was the conservative and 437 stepped protocol designed to gradually increase the oral ketamine dosages administrated over 438 the treatment period. Determining the minimum dose of a medication that is both effective and 439 tolerable involves striking a balance between minimising side effects and maximising the 440 achievable efficacy. Despite the extensive body of research examining the impact of ketamine 441 on diverse psychiatric disorders (Sanacora and Katz, 2018), the dose-response relationship and 442 optimal drug administration route for ketamine remains inadequately understood. The approach 443 employed in this study was conservative in both the maximum dosage administered and the frequency of dosage. The upper limit for oral ketamine dosage was set at 3 mg/kg, which differs 444 445 from earlier research findings that have reported dosages as high as 7 mg/kg (Hartberg et al., 446 2018). Moreover, previous research has described more frequent dosing schedules with oral ketamine (from once every 3 days to multiple doses per day) (Al Shirawi et al., 2017; Iglewicz et 447 448 al., 2015), which is in contrast to the frequency of administration in this study (once per week). 449 By adopting an initial lower dose, this protocol was designed to assess each patient's tolerance 450 to oral ketamine before gradually increasing it. This strategy has been proven successful in this 451 type of study in adults with TRD and chronic suicidality previously (Can et al., 2021). As a result, 452 the administration of low dose oral ketamine was well received and tolerated by study participants, with the majority of reported side effects being mild and transient. Importantly, all 453 reported side effects from oral ketamine were resolved prior to a participant's discharge from the 454 455 study. Comparatively, IV administration of ketamine has been correlated with a higher incidence of adverse effects compared to oral administration, and have encompassed physical 456 457 manifestations such as headaches, dizziness, alterations in vital signs, as well as acute mental

manifestations such as dissociation, anxiety, and agitation (Short et al., 2018). Additional study
in the oral ketamine space has indicated that the extended-release formulation of oral ketamine
also offers enhanced tolerability in relation to physical symptoms and dissociations (Glue et al.,
2020). These results offer a solid foundation to continue exploring oral ketamine as a safe, welltolerated form of ketamine treatment.

463 There were several notable limitations associated with this study that need to be 464 acknowledged. Firstly, the study sample size (n=22) was relatively small and an assessment of 465 the findings must be conducted with this in mind. Secondly, the study was open-label, with 466 neither a placebo/active control nor a comparator study group for the oral ketamine treatment 467 group, which limits the generalisability of the findings to the population level. Thirdly, the 468 participants were permitted to continue with their existing treatment programs (both 469 psychological interventions and psychopharmacological medications), and oral ketamine was 470 administrated to participants as an augmentation. Given this, it is difficult to disentangle the 471 contribution of the ongoing, concurrent medications/treatments. When viewed from this angle, 472 one cannot rule out the possibility of combined or synergic effects brought about by the 473 interaction of ketamine with other treatments. However, despite these limitations, this study 474 represents a "real-world" trial of how oral ketamine could be integrated into the ongoing 475 treatment programs of patients with PTSD and demonstrates that this treatment approach is 476 feasible and well-tolerated in this population.

477 In contrast to conventional antidepressants (which focus primarily on monoaminergic neurotransmitters and have slow-acting effects), ketamine (via its rapid-acting glutamatergic 478 479 effects) offers an important and viable treatment option for symptoms of PTSD. In this respect, 480 this open-label clinical trial has demonstrated that low dose oral ketamine is feasible, safe, and 481 tolerable in adults with PTSD. More research is now required in the form of larger, randomised 482 and blinded trials to elucidate oral ketamine's optimal dosage levels, treatment timing/protocol, 483 and further characterise short- and long-term safety in PTSD treatment. With clinical outcomes 484 comparable to IV infusion studies, this present study has demonstrated that low dose oral 485 ketamine is a safe option for the treatment of PTSD and has contributed important additional 486 information to the growing research evidence for ketamine in mental health treatment.

487

# 488 Acknowledgement

The authors express their sincere gratitude to the participants of the OKTOP study. The funding
for this project was provided by the internal budget of the Thompson Institute. The authors
declare that they have no conflict of interest.

medRxiv preprint doi: https://doi.org/10.1101/2024.11.26.24318024; this version posted December 5, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

### 492 References

- Adetunji, B., Mathews, M., Williams, A., Budur, K., Mathews, M., Mahmud, J., Osinowo, T., 2005. Use
  of antipsychotics in the treatment of post-traumatic stress disorder. Psychiatry (Edgmont) 2, 43-47.
- 496 Al Shirawi, M.I., Kennedy, S.H., Ho, K.T., Byrne, R., Downar, J., 2017. Oral Ketamine in Treatment-497 Resistant Depression: A Clinical Effectiveness Case Series. J Clin Psychopharmacol 37, 464-467.
- 498
  499 American Psychiatric Association, 2013. Diagnostic and statistical manual of mental disorders: DSM500 5. American Psychiatric Publishing, Inc., Arlington, VA, US.
- Andrade, C., 2019. Oral Ketamine for Depression, 1: Pharmacologic Considerations and Clinical
  Evidence. J Clin Psychiatry 80.
- 504

501

- Asnis, G.M., Kohn, S.R., Henderson, M., Brown, N.L., 2004. SSRIs versus Non-SSRIs in Post-traumatic
   Stress Disorder. Drugs 64, 383-404.
- 508 Australian Bureau of Statistics 2020-21. National Study of Mental Health and Wellbeing.
- 509

507

- 510 Bech, P., Olsen, L.R., Kjoller, M., Rasmussen, N.K., 2003. Measuring well-being rather than the
- absence of distress symptoms: a comparison of the SF-36 Mental Health subscale and the WHO-Five
   Well-Being Scale. Int J Methods Psychiatr Res 12, 85-91.
- 513
- Beck, A.T., Kovacs, M., Weissman, A., 1979. Assessment of suicidal intention: the Scale for Suicide
  Ideation. J Consult Clin Psychol 47, 343-352.
- 516

Benjet, C., Bromet, E., Karam, E.G., Kessler, R.C., McLaughlin, K.A., Ruscio, A.M., Shahly, V., Stein,
D.J., Petukhova, M., Hill, E., Alonso, J., Atwoli, L., Bunting, B., Bruffaerts, R., Caldas-de-Almeida, J.M.,
de Girolamo, G., Florescu, S., Gureje, O., Huang, Y., Lepine, J.P., Kawakami, N., Kovess-Masfety, V.,
Medina-Mora, M.E., Navarro-Mateu, F., Piazza, M., Posada-Villa, J., Scott, K.M., Shalev, A., Slade, T.,
ten Have, M., Torres, Y., Viana, M.C., Zarkov, Z., Koenen, K.C., 2016. The epidemiology of traumatic

- event exposure worldwide: results from the World Mental Health Survey Consortium. Psychol Med
  46, 327-343.
- Berger, W., Mendlowicz, M.V., Marques-Portella, C., Kinrys, G., Fontenelle, L.F., Marmar, C.R.,
  Figueira, I., 2009. Pharmacologic alternatives to antidepressants in posttraumatic stress disorder: a
- 527 systematic review. Prog Neuropsychopharmacol Biol Psychiatry 33, 169-180.
- 528
  529 Berman, R.M., Cappiello, A., Anand, A., Oren, D.A., Heninger, G.R., Charney, D.S., Krystal, J.H., 2000.
  530 Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 47, 351-354.
- 531
- Blevins, C.A., Weathers, F.W., Davis, M.T., Witte, T.K., Domino, J.L., 2015. The Posttraumatic Stress
  Disorder checklist for DSM-5 (PCL-5): Development and initial psychometric evaluation. J Trauma
  Stress 28, 489-498.
- 535
- Bremner, J.D., Krystal, J.H., Putnam, F.W., Southwick, S.M., Marmar, C., Charney, D.S., Mazure, C.M.,
  1998. Measurement of dissociative states with the Clinician-Administered Dissociative States Scale
  (CADSS). J Trauma Stress 11, 125-136.
- 539
- 540 Brunet, A., Sapkota, R.P., Guragain, B., Tremblay, J., Saumier, D., Kirmayer, L.J., 2021. Tackling the
- 541 global problem of traumatic stress in low-income countries: a pilot clinical trial comparing
- reconsolidation therapy to paroxetine in Nepal. BMC Psychiatry 21, 434.

E12	
545 544	Can, A.T., Hermens, D.F., Dutton, M., Gallay, C.C., Jensen, E., Jones, M., Scherman, J., Beaudequin,
545 546 547	D.A., Yang, C., Schwenn, P.E., Lagopoulos, J., 2021. Low dose oral ketamine treatment in chronic suicidality: An open-label pilot study. Transl Psychiatry 11, 101.
548 549 550	Cohen, S., Kamarck, T., Mermelstein, R., 1983. A global measure of perceived stress. J Health Soc Behav 24, 385-396.
551 552 553 554	Elhai, J.D., Gray, M.J., Kashdan, T.B., Franklin, C.L., 2005. Which instruments are most commonly used to assess traumatic event exposure and posttraumatic effects?: A survey of traumatic stress professionals. J Trauma Stress 18, 541-545.
555 556 557	Ferguson, J.M., 2001. SSRI Antidepressant Medications: Adverse Effects and Tolerability. Prim Care Companion J Clin Psychiatry 3, 22-27.
558 559 560 561	Franken, I.H., Rassin, E., Muris, P., 2007. The assessment of anhedonia in clinical and non-clinical populations: further validation of the Snaith-Hamilton Pleasure Scale (SHAPS). J Affect Disord 99, 83-89.
562 563 564	Frazer, A., Benmansour, S., 2002. Delayed pharmacological effects of antidepressants. Mol Psychiatry 7 Suppl 1, S23-28.
565 566 567 568	Germain, A., Hall, M., Krakow, B., Katherine Shear, M., Buysse, D.J., 2005. A brief sleep scale for Posttraumatic Stress Disorder: Pittsburgh Sleep Quality Index Addendum for PTSD. J Anxiety Disord 19, 233-244.
569 570 571 572	Glue, P., Medlicott, N.J., Neehoff, S., Surman, P., Lam, F., Hung, N., Hung, C.T., 2020. Safety and efficacy of extended release ketamine tablets in patients with treatment-resistant depression and anxiety: open label pilot study. Ther Adv Psychopharmacol 10, 2045125320922474.
573 574 575	Goldman, H.H., Skodol, A.E., Lave, T.R., 1992. Revising axis V for DSM-IV: a review of measures of social functioning. Am J Psychiatry 149, 1148-1156.
576 577 578	Green, B., 2013. Post-traumatic stress disorder: New directions in pharmacotherapy. Advances in Psychiatric Treatment 19, 181-190.
579 580 581 582	Hartberg, J., Garrett-Walcott, S., De Gioannis, A., 2018. Impact of oral ketamine augmentation on hospital admissions in treatment-resistant depression and PTSD: a retrospective study. Psychopharmacology (Berl) 235, 393-398.
583 584 585 586	Iglewicz, A., Morrison, K., Nelesen, R.A., Zhan, T., Iglewicz, B., Fairman, N., Hirst, J.M., Irwin, S.A., 2015. Ketamine for the treatment of depression in patients receiving hospice care: a retrospective medical record review of thirty-one cases. Psychosomatics 56, 329-337.
587 588 589	Jeffreys, M., Capehart, B., Friedman, M.J., 2012. Pharmacotherapy for posttraumatic stress disorder: review with clinical applications. J Rehabil Res Dev 49, 703-715.
590 591 592	Kim, J., Farchione, T., Potter, A., Chen, Q., Temple, R., 2019. Esketamine for Treatment-Resistant Depression - First FDA-Approved Antidepressant in a New Class. N Engl J Med 381, 1-4. Kurdi, M.S., Theerth, K.A., Deva, R.S., 2014. Ketamine: Current applications in anesthesia, pain, and

593 critical care. Anesth Essays Res 8, 283-290.

50/	
595	López-Oieda, W., Hurley, R.A., 2022, Extended Reality Technologies: Expanding Therapeutic
596	Approaches for PTSD. J Neuropsychiatry Clin Neurosci 34, A4-5.
597	
598	Lovibond, S.H., Lovibond, P.F., 1995. Manual for the Depression Anxiety Stress Scales (2nd Ed.).
599	Psychology Foundation, Sydney.
600	
601	Mills. K.L., McFarlane, A.C., Slade, T., Creamer, M., Silove, D., Teesson, M., Brvant, R., 2011.
602	Assessing the prevalence of trauma exposure in epidemiological surveys. Aust N Z J Psychiatry 45,
603	407-415.
604	
605	Montgomery, S.A., Asberg, M., 1979. A new depression scale designed to be sensitive to change. Br J
606	Psychiatry 134, 382-389.
607	
608	Muhorakeye, O., Biracyaza, E., 2021. Exploring Barriers to Mental Health Services Utilization at
609	Kabutare District Hospital of Rwanda: Perspectives From Patients. Front Psychol 12, 638377.
610	
611	Norman, S., Hamblen, J., Schnurr, P.P., 2023. Overview of Psychotherapy for PTSD, PTSD: National
612	Center for PTSD. US. Department of Veterans Affairs, online.
613	
614	Overall, J.E., Gorham, D.R., 1988. The Brief Psychiatric Rating Scale (BPRS): recent developments in
615	ascertainment and scaling. Psychopharmacology bulletin.
616	
617	Ragnhildstveit, A., Roscoe, J., Bass, L.C., Averill, C.L., Abdallah, C.G., Averill, L.A., 2023. The potential
618	of ketamine for posttraumatic stress disorder: a review of clinical evidence. Ther Adv
619	Psychopharmacol 13, 20451253231154125.
620	
621	Rush, A.J., Fava, M., Wisniewski, S.R., Lavori, P.W., Trivedi, M.H., Sackeim, H.A., Thase, M.E.,
622	Nierenberg, A.A., Quitkin, F.M., Kashner, T.M., Kupfer, D.J., Rosenbaum, J.F., Alpert, J., Stewart, J.W.,
623	McGrath, P.J., Biggs, M.M., Shores-Wilson, K., Lebowitz, B.D., Ritz, L., Niederene, G., Group, S.D.I.,
024 625	2004. Sequenced treatment alternatives to relieve depression (STAR*D). rationale and design.
625	
627	Sanacora, G., Katz, R., 2018, Ketamine: A Review for Clinicians, Focus (Am Psychiatr Publ) 16, 243-
628	250
629	
630	Sareen, L. 2014. Posttraumatic stress disorder in adults: impact. comorbidity, risk factors, and
631	treatment. Can J Psychiatry 59, 460-467.
632	
633	Short, B., Fong, J., Galvez, V., Shelker, W., Loo, C.K., 2018. Side-effects associated with ketamine use
634	in depression: a systematic review. Lancet Psychiatry 5, 65-78.
635	
636	Thomas, E., Stein, D.J., 2017. Novel pharmacological treatment strategies for posttraumatic stress
637	disorder. Expert Rev Clin Pharmacol 10, 167-177.
638	
639	Veraart, J.K.E., van Westenbrugge, M., van Wulfften Palthe, J.E., van der Meij, A., Schoevers, R.A., de
640	Jong, J., 2023. Repeated oral esketamine in patients with treatment resistant depression and
641	comorbid posttraumatic stress disorder. Heliyon 9, e15883.
642	
643	Watkins, L.E., Sprang, K.R., Rothbaum, B.O., 2018. Treating PTSD: A Review of Evidence-Based
644	Psychotherapy Interventions. Front Behav Neurosci 12, 258.

645

- 646 Weathers, F.W., Bovin, M.J., Lee, D.J., Sloan, D.M., Schnurr, P.P., Kaloupek, D.G., Keane, T.M., Marx,
- 647 B.P., 2018. The Clinician-Administered PTSD Scale for DSM-5 (CAPS-5): Development and initial
- 648 psychometric evaluation in military veterans. Psychol Assess 30, 383-395.
- 649
- 650 Young, R.C., Biggs, J.T., Ziegler, V.E., Meyer, D.A., 1978. A rating scale for mania: reliability, validity
- and sensitivity. Br J Psychiatry 133, 429-435. 651

652